Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn shared a recent post by Andrew J. Pellatt et al. published in JCO Oncology Practice.
“With so many KRAS targeted drugs entering clinical trials pleased to share our editorial in American Society of Clinical Oncology (ASCO) journal JCO OP
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.”
Authors: Andrew J. Pellatt et al.
